Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy - PubMed
4 hours ago
- #Alzheimer's disease
- #biomarkers
- #immunotherapy
- New Alzheimer's disease treatments using anti-amyloid-β immunotherapy are raising concerns.
- Trials supporting lecanemab and donanemab approvals have methodological flaws.
- Benefits may be smaller than the minimal clinically important difference or absent due to exclusion of patients with poor tolerance.
- Treatment increases amyloid-related imaging abnormalities, suggesting local tissue damage.
- Linked to brain volume loss.
- Doubts about whether regulators are adequately balancing risks and benefits.